Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Government Injects $1m Into Diabetes Research


Government Injects $1 Million Into Canterbury Scientific Diabetes Research

Press release, 24 September 2012, Canterbury Scientific, Christchurch, New Zealand: Canterbury Scientific, in partnership with the University of Canterbury’s Biomolecular Interaction Centre, is set to receive nearly $1 million in funding from the Ministry of Business, Innovation & Employment. The investment is one of 31 projects selected under the 2012 High-Value Manufacturing and Services Research Fund announced recently by Minister Steven Joyce and will enable research into tests for the secondary complications of diabetes.

The Diagnostic Markers for Diabetic Complications research project is expected to lead to the development of new commercial tests to identify patients at high risk of diabetic complications such as heart disease, visual impairment, diabetic neuropathy and kidney disease. The researchers estimate revenue potential from such products at $5-10 million per year in export sales by 2020. In his announcement Mr Joyce highlighted export potential as a key priority in the funding selection process.

Canterbury Scientific will manufacture and market any resulting products, which would be complementary to their already successful HbA1c blood glucose test controls. The company will also provide an accelerated route-to-market by leveraging existing business models, high quality manufacturing processes and strong distribution relationships with global healthcare giants like Roche, Siemens and Beckman Coulter.

“The benefits of this diabetes research are wide-reaching. Not only will it further global scientific understanding around the triggers of diabetic complications, but it will also meet urgent needs to improve diabetic patient outcomes by ensuring at-risk patients receive close monitoring and early treatment, and reduce the impact on the health system,” said Canterbury Scientific CEO Dr Neil Pattinson.

Diabetes now affects 10% of the adult population according to the 2012 World Health Statistics Report. It is a rapidly escalating global health threat that is having a major effect on health care systems around the world; Diabetes New Zealand says that treatments for diabetes and its complications could consume up to 15% of the health budget by 2021. Early identification and intervention is key to reducing the economic burden of this disease.

“We have carved out a niche as a specialist provider of diagnostic test controls based on our commercial success with HbA1c. This injection of funding will be the catalyst for growing Canterbury Scientific to the next level through broader product offerings,” continued Pattinson. “With support from Industrial Research Ltd’s (IRL) new Christchurch-based protein science team and now funding from MBIE, we have enjoyed tremendous public sector validation and encouragement. There could be no stronger endorsement of our business strategy.”

The research project concept stemmed from recent international studies that found two biomarkers for diabetic retinopathy (vision impairment), and seeks to assess their potential as predictors of kidney and heart problems as well. The concept was further refined at Canterbury Scientific’s inaugural science symposium in March this year, which brought together more than 30 scientists and clinicians from the Universities of Canterbury (Biomolecular Interaction Centre), Otago (Christchurch School of Medicine), Cambridge and Shanghai as well as IRL and Canterbury Health Labs to promote innovation and collaboration, and consider new biomarker product opportunities. Other outcomes from the event include research on tests for heart failure, pre-eclampsia and pancreatitis.

Scientific Director and co-founder Dr Maurice Owen will lead the project on behalf of Canterbury Scientific, and work closely with University of Canterbury researchers Dr Renwick Dobson, Prof Juliet Gerrard and Prof Antony Fairbanks.

About Canterbury Scientific

Canterbury Scientific Ltd is a privately owned New Zealand medical device company founded out of the Canterbury District Health Board in 1985 by directors Prof Robin Carrell, Bryce Hawkins and Dr Maurice Owen. The company specialises in the development and production of quality HbA1c controls for haematology and clinical biochemistry tests which are prized for being highly reliable and ethical with enhanced stability and shelf life.

In February 2011, Canterbury Scientific opened a new $1.2m facility in Christchurch which has been specially furbished with modern sophisticated systems, including temperature and humidity control, to provide an advanced and sustainable environment comparable to world class manufacturing practices. The company was named as one of the Technology Investment Network’s Top 10 Hot Emerging Companies of 2011, a finalist in the Global Operator category of the 2012 Champion Canterbury Awards and a finalist in the Health and Science category of the New Zealand Innovators Awards. For more information visit www.canterburyscientific.com.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Keep Digging: Seabed Ironsands Miner TransTasman Tries Again

The first company to attempt to gain a resource consent to mine ironsands from the ocean floor in New Zealand's Exclusive Economic Zone has lodged a new application containing fresh scientific and other evidence it hopes will persuade regulators after their initial application was turned down in 2014. More>>

Wool Pulled: Duvets Sold As ‘Premium Alpaca’ Mostly Sheep’s Wool

Rotorua business Budge Collection Limited (Budge) and sole director, Sun Dong Kim, were convicted and fined a total of $71,250 in Auckland District Court after each pleading guilty to four charges of misrepresenting how much alpaca fibre was in their duvets. More>>

Reserve Bank: Labour Calls For Monetary Policy To Expand Goals

Labour's comments follow a speech today by RBNZ governor Graeme Wheeler in which Wheeler sought to answer critics who variously say he should stop lowering interest rates, lower them faster, or that inflation-targeting should no longer be the primary goal of the central bank's activities. More>>

ALSO:

BSA Extension And Sunday Morning Ads: Digital Convergence Bill Captures Online Content

Broadcasting Minister Amy Adams has today announced the Government’s plans to update the Broadcasting Act to better reflect today’s converged market... The Government considered four areas as part of its review into content regulation: classification requirements, advertising restrictions, election programming and contestable funding. More>>

ALSO:

March 2017: Commerce Commission Delays Decision On Fairfax-NZME

The Commerce Commission has delayed its decision on the proposed merger between NZME and Fairfax Media's New Zealand assets, saying the deal is complex and it needs more time to assess the impact on both news content and the advertising market. More>>

ALSO:

Plan Plan: Permanent Independent Hearings Panel Proposed For Planning

The Productivity Commission recommends creating a permanent independent hearings panel like the one that cut through local politics to settle Auckland’s Unitary Plan, for the whole country. More>>

ALSO:

Statistics: NZ Jobless Rate Falls To 5.1% Under New Methodology

New Zealand's unemployment rate fell more than expected in the second quarter as Statistics New Zealand adopted a new way of measuring the labour market to bring the country in line with international practices, and while a growing economy continued to support jobs growth. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news